Literature DB >> 16952513

Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.

Mirta Knoepfelmacher1, Debora L S Danilovic, Rubia H R Rosa Nasser, Berenice B Mendonça.   

Abstract

OBJECTIVE: To report the effect of cabergoline on ovarian hyperstimulation syndrome associated with gonadotropin-secreting pituitary adenomas.
DESIGN: Case report.
SETTING: Outpatient practice. PATIENT(S): Two women with menstrual irregularity, enlarged ovaries, high E(2), and normal gonadotropin levels. INTERVENTION(S): Cabergoline treatment and transsphenoidal surgery. MAIN OUTCOME MEASURE(S): Estradiol levels, transvaginal ultrasonography, and pituitary magnetic resonance imaging. Transsphenoidal surgery showed pituitary adenoma staining for LH in both patients. RESULT(S): Cabergoline was effective in reducing E(2) levels and decreasing ovarian size but ineffective in shrinking the pituitary adenomas. CONCLUSION(S): This is the first description of the effectiveness of cabergoline as the primary treatment of spontaneous ovarian hyperstimulation syndrome in patients with gonadotropin-producing pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952513     DOI: 10.1016/j.fertnstert.2006.01.055

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

2.  Delayed identification of massive pituitary apoplexy in pregnancy: A case report.

Authors:  Hari Sedai; Suraj Shrestha; Elisha Poddar; Pratima Sharma; Dipendra Dahal; Prajwal Khatiwada; Amit Pradhanang
Journal:  Int J Surg Case Rep       Date:  2022-09-27

3.  Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma.

Authors:  Odelia Cooper; Jordan L Geller; Shlomo Melmed
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-02-12

4.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

5.  Radiological illustration of spontaneous ovarian hyperstimulation syndrome.

Authors:  Kartik Mittal; Raj Koticha; Amit K Dey; Karan Anandpara; Rajat Agrawal; Madhva P Sarvothaman; Hemangini Thakkar
Journal:  Pol J Radiol       Date:  2015-04-28

6.  Follicle-stimulating hormone-secreting pituitary adenoma manifesting as recurrent ovarian cysts in a young woman--latent risk of unidentified ovarian hyperstimulation: a case report.

Authors:  Tomohiro Kawaguchi; Yoshikazu Ogawa; Kenji Ito; Mika Watanabe; Teiji Tominaga
Journal:  BMC Res Notes       Date:  2013-10-11

Review 7.  Updating the Landscape for Functioning Gonadotroph Tumors.

Authors:  Georgia Ntali; Cristina Capatina
Journal:  Medicina (Kaunas)       Date:  2022-08-08       Impact factor: 2.948

8.  MULTIPLE PITUITARY ADENOMAS WITH FUNCTIONAL FOLLICLE-STIMULATING HORMONE SECRETION LEADING TO OVARIAN HYPERSTIMULATION SYNDROME.

Authors:  Adva Eisenberg; Jennifer Mersereau; Anne F Buckley; Lauren Gratian
Journal:  AACE Clin Case Rep       Date:  2018-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.